Results of a Phase I-II Study of Fenretinide and Rituximab for Patients with B-Cell Lymphomas

被引：0
作者：
Cowan, Andrew J. [1 ]
Stevenson, Philip [2 ]
Gooley, Ted A. [2 ]
Frayo, Shani L. [2 ]
Oliveira, George R. [3 ]
Smith, Stephen D. [1 ,4 ]
Green, Damian J. [1 ,2 ]
Roden, Jennifer E. [5 ]
Pagel, John M. [6 ]
Wood, Brent L. [4 ,7 ]
Press, Oliver W. [1 ,4 ]
Gopal, Ajay K. [1 ,8 ]
机构：
[1] Univ Washington, Dept Med, Div Med Oncol, Seattle, WA USA
[2] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[3] Harvard Univ, Sch Med, Dept Radiol, MGH Hosp, Boston, MA 02115 USA
[4] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA
[5] Univ Washington, Dept Med, Seattle, WA USA
[6] Swedish Med Ctr, Seattle, WA USA
[7] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA
[8] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Results of a phase I-II study of fenretinide and rituximab for patients with indolent B-cell lymphoma and mantle cell lymphoma
    Cowan, Andrew J.
    Stevenson, Phillip A.
    Gooley, Ted A.
    Frayo, Shani L.
    Oliveira, George R.
    Smith, Stephen D.
    Green, Damian J.
    Roden, Jennifer E.
    Pagel, John M.
    Wood, Brent L.
    Press, Oliver W.
    Gopal, Ajay K.
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 176 (04) : 583 - 590
  • [2] Is there need for radioimmunotherapy? Results of a phase I/II study in patients with indolent B-cell lymphomas using lutetium-177-DOTA-rituximab
    Forrer, F.
    Oechslin-Oberholzer, C.
    Campana, B.
    Maecke, H. R.
    Mueller-Brand, J.
    Lohri, A.
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 56 (06) : 544 - 550
  • [3] Radioimmunotherapy with 177Lu-DOTA-Rituximab. Final results of a phase I/II study in 31 patients with relapsing follicular, mantle cell and other indolent B-cell lymphomas
    Forrer, F.
    Oechslin-Oberholzer, C.
    Campana, C.
    Maecke, H. R.
    Mueller-Brand, J.
    Lohri, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S294 - S294
  • [4] Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study
    Jermann, M
    Jost, LM
    Taverna, C
    Jacky, E
    Honegger, HP
    Betticher, DC
    Egli, F
    Kroner, T
    Stahel, RA
    ANNALS OF ONCOLOGY, 2004, 15 (03) : 511 - 516
  • [5] Radioimmunotherapy with 177Lu-DOTA-Rituximab: Final Results of a Phase I/II Study in 31 Patients with Relapsing Follicular, Mantle Cell, and Other Indolent B-Cell Lymphomas
    Forrer, Flavio
    Oechslin-Oberholzer, Catharina
    Campana, Benedetta
    Herrmann, Richard
    Maecke, Helmut R.
    Mueller-Brand, Jan
    Lohri, Andreas
    JOURNAL OF NUCLEAR MEDICINE, 2013, 54 (07) : 1045 - 1052
  • [6] Phase II Trial of Lenalidomide - Rituximab ± Dexamethasone in Relapsed or Refractory Indolent B-Cell or Mantle Cell Lymphomas Resistant to Rituximab
    Ahmadi, Tahamtan
    Chong, Elise A.
    Gordon, Amanda
    Aqui, Nicole A.
    Xu, YinYan
    Svoboda, Jakub
    Nasta, Sunita D.
    Schuster, Stephen J.
    BLOOD, 2011, 118 (21) : 122 - 123
  • [7] Stage I-II diffuse large B-cell lymphoma treated with rituximab and chemotherapy with or without radiotherapy
    Binkley, Michael S.
    Hiniker, Susan M.
    Younes, Sheren
    Yoo, Christopher
    Wignarajah, Anjali
    Jin, Michael
    Guo, H. Henry
    Gupta, Neel K.
    Natkunam, Yasodha
    Advani, Ranjana H.
    Hoppe, Richard T.
    LEUKEMIA & LYMPHOMA, 2021, 62 (08) : 1840 - 1849
  • [8] Phase II Trial of Lenalidomide - Dexamethasone - Rituximab In Relapsed or Refractory Indolent B-Cell or Mantle Cell Lymphomas Resistant to Rituximab
    Ahmadi, Tahamtan
    Chong, Elise A.
    Gordon, Amanda
    Leinbach, Leah
    Aqui, Nicole A.
    Nasta, Sunita D.
    Svoboda, Jakub
    Goldstein, Steven C.
    Schuster, Stephen J.
    BLOOD, 2010, 116 (21) : 1616 - 1616
  • [9] A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
    Tuscano, Joseph M.
    Maverakis, Emanual
    Groshen, Susan
    Tsao-Wei, Denice
    Luxardi, Guillaume
    Merleev, Alexander A.
    Beaven, Anne
    DiPersio, John F.
    Popplewell, Leslie
    Chen, Robert
    Kirschbaum, Mark
    Schroeder, Mark A.
    Newman, Edward M.
    CLINICAL CANCER RESEARCH, 2019, 25 (23) : 7004 - 7013
  • [10] Phase II Trial of Lenalidomide - Dexamethasone - Rituximab in Relapsed or Refractory Indolent B-Cell or Mantle Cell Lymphomas Resistant to Rituximab.
    Ahmadi, Tahamtan
    Chong, Elise A.
    Gordon, Amanda
    Aqui, Nicole A.
    Downs, Lisa H.
    Leinbach, Leah
    Goldstein, Steven C.
    Nasta, Sunita D.
    Janofsky, Stephen
    Maniar, Tapan N.
    Svoboda, Jakub
    Schuster, Stephen J.
    BLOOD, 2009, 114 (22) : 677 - 677
12345